Crossmark

STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models

Crossref DOI link: https://doi.org/10.1186/s40425-019-0573-5

Published Online: 2019-04-29

Published Print: 2019-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Jing, Weiqing

McAllister, Donna

Vonderhaar, Emily P.

Palen, Katie

Riese, Matthew J.

Gershan, Jill

Johnson, Bryon D.

Dwinell, Michael B. https://orcid.org/0000-0001-5372-633X
Funding

Funding for this research was provided by:

National Cancer Institute (R01 CA178960)

National Institute of General Medical Sciences (T32GM080202)

Advancing a Healthier Wisconsin Endowment at the Medical College of Wisconsin (NA)
License Information

Text and Data Mining valid from 2019-04-29
More Information

Article History

Received: 2 November 2018

Accepted: 20 March 2019

First Online: 29 April 2019

Ethics approval and consent to participate

: Not applicable.

: Not applicable.

: M.B. Dwinell has ownership interests in Protein Foundry, LLC which produces ultra-pure recombinant chemokines for research (). The other authors have no conflict of interest to disclose.

: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.